FindTrial
Sign In

Analysis for the prediction of systemic therapies in patients with locally advanced hepatocellular carcinoma

Analysis of Prognostic factors and Biomarkers for the prediction of systemic therapies including tyrosine kinase inhibitors and immunotherapy response in patients with locally advanced hepatocellular carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004206
Enrollment
400
Registered
2019-08-19
Start date
2019-09-01
Completion date
Unknown
Last updated
2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Seoul National University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with histologically confirmed locally advanced or metastatic HCC, which was judged not to be eligible for surgical resection, liver transplantation or radiofrequency ablation

Exclusion criteria

Exclusion criteria: Patients with histologically confirmed fibrolamellar type HCC or combined type with cholangiocarcinoma Patients who refuse to participate in the study

Design outcomes

Secondary

MeasureTime frame
Treatment response duration;Disease control rate;Time to progression;Progression free survival;Overall survival—

Primary

MeasureTime frame
Objective response (complete response rate + partial response rate)—

Countries

Korea, Republic of

Contacts

Public ContactSu Jong Yu

Seoul National University Hospital

ydoctor2@hanmail.net+82-2-2072-2228

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026